These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21435387)

  • 1. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?
    Guo J; Bourre L; Soden DM; O'Sullivan GC; O'Driscoll C
    Biotechnol Adv; 2011; 29(4):402-17. PubMed ID: 21435387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical characterization techniques for lipid based delivery systems for siRNA.
    Kapoor M; Burgess DJ; Patil SD
    Int J Pharm; 2012 May; 427(1):35-57. PubMed ID: 21979250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic gene therapy. Present situation and future perspective.
    Gottschalk U; Chan S
    Arzneimittelforschung; 1998 Nov; 48(11):1111-20. PubMed ID: 9850435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies for cancer gene therapy: progress and opportunities.
    Cao S; Cripps A; Wei MQ
    Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):108-14. PubMed ID: 19671071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S; Zhao B; Jiang H; Wang B; Ma B
    J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes.
    Hossain S; Stanislaus A; Chua MJ; Tada S; Tagawa Y; Chowdhury EH; Akaike T
    J Control Release; 2010 Oct; 147(1):101-8. PubMed ID: 20620182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supramolecular assemblies in functional siRNA delivery: where do we stand?
    Aliabadi HM; Landry B; Sun C; Tang T; Uludağ H
    Biomaterials; 2012 Mar; 33(8):2546-69. PubMed ID: 22209641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y
    IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.